We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » District Court Invalidates AstraZeneca's Pulmicort Respules Patent
District Court Invalidates AstraZeneca's Pulmicort Respules Patent
A U.S. District Court in New Jersey ruled Friday that the patent protecting AstraZeneca's inhaled asthma drug Pulmicort Respules is invalid, opening the door to generic competition.